Triple O Research Institute, P.A.
Triple O Research Institute, P.A.
West Palm Beach, Florida, United States5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of GS-0415 and How It Works in People With HIV | HIV -1 Infection | Recruiting | Phase 1 | 2026-09-23 | NCT07719491 | |
| Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy | Blood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted disease | Recruiting | Phase 3 | 2026-08-14 | NCT07682961 | |
| Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy | HIV-1-infection | Active, not recruiting | Phase 3 | 2026-06-15 | NCT06333808 | |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | HIV-1 Infection | Active, not recruiting | Phase 2 | 2026-04-27 | NCT05729568 | |
| Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed | HIV-1-Infection | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-17 | NCT06544733 |